Syngene Accelerates Therapeutic Discovery with Target Focused-Modality Agnostic Approach and Deep Expertise Across Specialty Platforms (PROTACs, Conjugates, T-Cell, Gene Therapy)

Syngene accelerates discovery

Check out our interview with Kenneth Barr, SVP, Discovery Services, Syngene as he talks about targeted protein degradation emerging as a transformative new therapeutic modality.

Sygnene is accelerating therapeutic discovery and we’re thrilled they are a part of our Science Exchange Contracted™ network of 3,300+ CROs, CMOs, and academic labs offering their services to help research organizations accelerate drug discoveries and innovation. […]

Read More…

The Toxicology Insider Vol. 2: New Providers on Science Exchange

mouse

Expand your access to innovative toxicology services through the Science Exchange Network, as we are continuously adding new services and qualified providers. Here are four recent additions that could inspire your next breakthrough. Visit each provider’s online profile to learn more about the technologies listed. […]

Read More…

New on Science Exchange: Desktop 3D Bioprinting, Hardware-free Long-read NGS, Rethinking Clinical Trials

SE3D collagen

Expand your access to innovation through the Science Exchange Network, as we are continuously adding new services and qualified providers. Here are five recent additions that could inspire your next breakthrough. Visit each provider’s online profile to learn more about the technologies listed. […]

Read More…